Is the medication used to achieve the target intraocular pressure in glaucoma therapy of relevance? - An exemplary analysis on the basis of two beta-blockers

Progress in Retinal and Eye Research

Volumn 29, Issue 1, 2010, Pages 79-93

  Grieshaber, Matthias C ^a   Flammer, Josef ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Beta blocker; Betaxolol; Blood flow; Calcium channel; Glaucoma; IOP; Ischemia; Neuroprotection; Optic nerve; Reperfusion; Retina; Side effect; Timolol; Vasodilatation; Visual field

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM ION; NIFEDIPINE; NILVADIPINE; NIMODIPINE; SEROTONIN 1A RECEPTOR; SEROTONIN RECEPTOR; SODIUM CHANNEL BLOCKING AGENT; TIMOLOL;

ADRENERGIC SYSTEM; CILIARY BODY; CLINICAL TRIAL; DETERIORATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TISSUE LEVEL; EYE BLOOD FLOW; GLAUCOMA; HUMAN; IN VITRO STUDY; INTRAOCULAR PRESSURE; LOW DRUG DOSE; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; RETINA GANGLION CELL; RETINA INJURY; REVIEW; SINGLE DRUG DOSE; TREATMENT OUTCOME; VISUAL FIELD;

ADRENERGIC BETA-ANTAGONISTS; BETAXOLOL; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; TIMOLOL; VISUAL FIELDS;

EID: 74749093360     PISSN: 13509462     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.preteyeres.2009.08.002     Document Type: Review

References (208)

1. Allen R.C., and Epstein D.L. Additive effect of betaxolol and epinephrine in primary open angle glaucoma. Arch. Ophthalmol. 104 (1986) 1178-1184
2. Altan-Yaycioglu R., Turker G., Akdol S., Acunas G., and Izgi B. The effects of beta-blockers on ocular blood flow in patients with primary open angle glaucoma: a color Doppler imaging study. Eur. J. Ophthalmol. 11 (2001) 37-46
3. Araie M., Azuma I., and Kitazawa Y. Influence of topical betaxolol and timolol on visual field in Japanese open-angle glaucoma patients. Jpn. J. Ophthalmol. 47 (2003) 199-207
4. Araie M., and Muta K. Effect of long-term topical betaxolol on tissue circulation in the iris and optic nerve head. Exp. Eye Res. 64 (1997) 167-172
5. Baptiste D.C., Hartwick A.T., Jollimore C.A., Baldridge W.H., Chauhan B.C., Tremblay F., and Kelly M.E. Comparison of the neuroprotective effects of adrenoceptor drugs in retinal cell culture and intact retina. Invest. Ophthalmol. Vis. Sci. 43 (2002) 2666-2676
6. Barnett N.L., and Osborne N.N. The presence of serotonin (5-HT1) receptors negatively coupled to adenylate cyclase in rabbit and human iris-ciliary processes. Exp. Eye Res. 57 (1993) 209-216
7. Bartels S.P., Lee S.R., and Neufeld A.H. The effects of forskolin on cyclic AMP, intraocular pressure and aqueous humor formation in rabbits. Curr. Eye Res. 6 (1987) 307-320
8. Bergstrand I.C., Heijl A., Wollmer P., Hansen F., and Harris A. Timolol increased retrobulbar flow velocities in untreated glaucoma eyes but not in ocular hypertension. Acta Ophthalmol. Scand. 79 (2001) 455-461
9. Bessho H., Suzuki J., and Tobe A. Vascular effects of betaxolol, a cardioselective beta-adrenoceptor antagonist, in isolated rat arteries. Jpn. J. Pharmacol. 55 (1991) 351-358
10. Boehm A.G., Breidenbach K.A., Pillunat L.E., Bernd A.S., Mueller M.F., and Koeller A.U. Visual function and perfusion of the optic nerve head after application of centrally acting calcium-channel blockers. Graefes Arch. Clin. Exp. Ophthalmol. 241 (2003) 34-38
11. Bose S., Piltz J.R., and Breton M.E. Nimodipine, a centrally active calcium antagonist, exerts a beneficial effect on contrast sensitivity in patients with normal-tension glaucoma and in control subjects. Ophthalmology 102 (1995) 1236-1241
12. Brennan M.C., Martin X.D., Heinrich T., and Lichter P.R. Timolol influences serotonin content in human aqueous humor. Invest. Ophthalmol. Vis. Sci. 31 Suppl. (1990) 336
13. ++. Klin Monatsbl Augenheilkd 219 (2002) 268-272
14. Bromberg B.B., Gregory D.S., and Sears M.L. Beta-adrenergic receptors in ciliary processes of the rabbit. Invest. Ophthalmol. Vis. Sci. 19 (1980) 203-207
15. Bron A.J., Chidlow G., Melena J., and Osborne N.N. Beta-blockers in the treatment of glaucoma. In: Orgul S., and Flammer J. (Eds). Pharmacotherapy in Glaucoma (2000), Hans Huber Verlag, Bern 79-113
16. 2+ channels and anoxic injury in rat CNS white matter. J. Neurophysiol. 85 (2001) 900-911
17. Carenini A.B., Sibour G., and Boles Carenini B. Differences in the longterm effect of timolol and betaxolol on the pulsatile ocular blood flow. Surv. Ophthalmol. 38 Suppl. (1994) S118-S124
18. Chaudhary P., Ahmed F., and Sharma S.C. MK801-a neuroprotectant in rat hypertensive eyes. Brain Res. 792 (1998) 154-158
19. Chauhan B.C., and Drance S.M. The relationship between intraocular pressure and visual field progression in glaucoma. Graefes Arch. Clin. Exp. Ophthalmol. 230 (1992) 521-526
20. Chen Y., McCarron R.M., Azzam N., Bembry J., Reutzler C., Lenz F.A., and Spatz M. Endothelin-1 and nitric oxide affect human cerebromicrovascular endothelial responses and signal transduction. Acta Neurochir. Suppl. 76 (2000) 131-135
21. Chen Y.N., Yamada H., Mao W., Matsuyama S., Aihara M., and Araie M. Hypoxia-induced retinal ganglion cell death and the neuroprotective effects of beta-adrenergic antagonists. Brain Res. 1148 (2007) 28-37
22. Cheon E.W., Park C.H., Kang S.S., Cho G.J., Yoo J.M., Song J.K., and Choi W.S. Nitric oxide synthase expression in the transient ischemic rat retina: neuroprotection of betaxolol. Neurosci. Lett. 330 (2002) 265-269
23. Cheon E.W., Park C.H., Kang S.S., Cho G.J., Yoo J.M., Song J.K., and Choi W.S. Betaxolol attenuates retinal ischemia/reperfusion damage in the rat. Neuroreport 14 (2003) 1913-1917
24. Chidlow G., Le Corre S., and Osborne N.N. Localization of 5- hydroxytryptamine1A and 5-hydroxytryptamine7 receptors in rabbit ocular and brain tissues. Neuroscience 87 (1998) 675-689
25. Chidlow G., Nash M.S., De Santis L.M., and Osborne N.N. The 5- HT(1A)Receptor agonist 8-OH-DPAT lowers intraocular pressure in normotensive NZW rabbits. Exp. Eye Res. 69 (1999) 587-593
26. (+) channels: comparison with other beta-adrenoceptor antagonists. Br. J. Pharmacol. 130 (2000) 759-766
27. Chidlow G., Cupido A., Melena J., and Osborne N.N. Flesinoxan, a 5-HT1A receptor agonist/alpha 1-adrenoceptor antagonist, lowers intraocular pressure in NZW rabbits. Curr. Eye Res. 23 (2001) 144-153
28. Chidlow G., and Osborne N.N. Antagonism of muscarinic receptors in the rabbit iris-ciliary body by 8-OH-DPAT and other 5-HT1A receptor agonists. J. Neural Transm. 104 (1997) 1015-1025
29. Chiou G.C., and Chen Y.J. Effects of antiglaucoma drugs on ocular blood flow in ocular hypertensive rabbits. J. Ocul. Pharmacol. 9 (1993) 13-24
30. Chiu S.Y., Zhou L., Zhang C.L., and Messing A. Analysis of potassium channel functions in mammalian axons by gene knockouts. J. Neurocytol 28 (1999) 349-364
31. Chu T.C., Ogidigben M.J., and Potter D.E. 8OH-DPAT-Induced ocular hypotension: sites and mechanisms of action. Exp. Eye Res. 69 (1999) 227-238
32. Chung H.S., Harris A., Evans D.W., Kagemann L., Garzozi H.J., and Martin B. Vascular aspects in the pathophysiology of glaucomatous optic neuropathy. Surv. Ophthalmol. 43 Suppl 1 (1999) S43-S50
33. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am. J. Ophthalmol. 126 (1998) 487-497
34. Collignon-Brach J. Long-term effect of ophthalmic beta-adrenoceptor antagonists on intraocular pressure and retinal sensitivity in primary open-angle glaucoma. Curr. Eye Res. 11 (1992) 1-3
35. Collignon-Brach J. Longterm effect of topical beta-blockers on intraocular pressure and visual field sensitivity in ocular hypertension and chronic open-angle glaucoma. Surv. Ophthalmol. 38 Suppl. (1994) S149-S155
36. Collignon N.J., and Collignon-Brach J.D. Effect of topical betablockers on human retinal vessels diameters. Int. Ophthalmol 21 (1997) 199-203
37. Costagliola C., Scibelli G., Fasano M.L., Ferrara L.A., and Mastropasqua L. Effect of oral ketanserin administration on intraocular pressure in glaucomatous patients. Exp. Eye Res. 52 (1991) 507-510
38. Crosson C.E., Willis J.A., and Potter D.E. Effect of the calcium antagonist, nifedipine, on ischemic retinal dysfunction. J. Ocul. Pharmacol. 6 (1990) 293-299
39. Dahlin D.C., Curtis M.A., De Santis L., and Struble C.B. Distribution of betaxolol to posterior ocular tissue of the cynomolgus monkey following a 30- day BID topical ocular regimen of Betoptic-S. Invest. Ophthalmol. Vis. Sci. (2000) S509
40. Daugeliene L., Yamamoto T., and Kitazawa Y. Effect of trabeculectomy on visual field in progressive normal-tension glaucoma. Jpn. J. Ophthalmol. 42 (1998) 286-292
41. Daugeliene L., Yamamoto T., and Kitazawa Y. Risk factors for visual field damage progression in normal-tension glaucoma eyes. Graefes Arch. Clin. Exp. Ophthalmol. 237 (1999) 105-108
42. Diestelhorst M., and Krieglstein G.K. The effect of betablockers with and without ISA on tonographic outflow facility. Int. Ophthalmol. 13 (1989) 63-65
43. + channels: electrifying regulators of synaptic terminal excitability. Trends Neurosci. 27 (2004) 210-217
44. Dong Y., Ishikawa H., Wu Y., Shimizu K., Goseki T., and Yoshitomi T. Effect and mechanism of betaxolol and timolol on vascular relaxation in isolated rabbit ciliary artery. Jpn. J. Ophthalmol. 50 (2006) 504-508
45. Doshi A., Kreidl K.O., Lombardi L., Sakamoto D.K., and Singh K. Nonprogressive glaucomatous cupping and visual field abnormalities in young Chinese males. Ophthalmology 114 (2007) 472-479
46. Drance S.M. A comparison of the effects of betaxolol, timolol, and pilocarpine on visual function in patients with open-angle glaucoma. J. Glaucoma 7 (1998) 247-252
47. Drance S.M., Douglas G.R., Wijsman K., Schulzer M., and Britton R.J. Response of blood flow to warm and cold in normal and low-tension glaucoma patients. Am. J. Ophthalmol. 105 (1988) 35-39
48. Drance S., Anderson D.R., and Schulzer M. Risk factors for progression of visual field abnormalities in normal-tension glaucoma. Am. J. Ophthalmol. 131 (2001) 699-708
49. Ederer F., Gaasterland D.A., Dally L.G., Kim J., VanVeldhuisen P.C., Blackwell B., Prum B., Shafranov G., Allen R.C., and Beck A. The Advanced Glaucoma Intervention Study (AGIS): 13. Comparison of treatment outcomes within race: 10-year results. Ophthalmology 111 (2004) 651-664
50. Evans D.W., Harris A., and Cantor L.B. Primary open-angle glaucoma patients characterized by ocular vasospasm demonstrate a different ocular vascular response to timolol versus betaxolol. J. Ocul. Pharmacol. Ther. 15 (1999) 479-487
51. Fargin A., Raymond J.R., Lohse M.J., Kobilka B.K., Caron M.G., and Lefkowitz R.J. The genomic clone G-21 which resembles a beta-adrenergic receptor sequence encodes the 5-HT1A receptor. Nature 335 (1988) 358-360
52. Feghali J.G., Kaufman P.L., Radius R.L., and Mandell A.I. A comparison of betaxolol and timolol in open angle glaucoma and ocular hypertension. Acta Ophthalmol 66 (1988) 180-186
53. Fern R., and Ransom B.R. Ischemic injury of optic nerve axons: the nuts and bolts. Clin. Neurosci. 4 (1997) 246-250
54. Flammer J. Psychophysical mechanisms and treatment of vasospastic disorders in normal-tension glaucoma. Bull. Soc. Belge Ophtalmol 244 (1992) 129-134
55. Flammer J., and Drance S.M. Effect of acetazolamide on the differential threshold. Arch. Ophthalmol. 101 (1983) 1378-1380
56. Flammer J., and Drance S.M. Reversibility of a glaucomatous visual field defect after acetazolamide therapy. Can. J. Ophthalmol. 18 (1983) 139-141
57. Flammer J., Haefliger I.O., Orgul S., and Resink T. Vascular dysregulation: a principal risk factor for glaucomatous damage?. J. Glaucoma 8 (1999) 212-219
58. Flammer J., Orgul S., Costa V.P., Orzalesi N., Krieglstein G.K., Serra L.M., Renard J.P., and Stefansson E. The impact of ocular blood flow in glaucoma. Prog. Retin. Eye Res. 21 (2002) 359-393
59. Flammer J., and Mozaffarieh M. What is the present pathogenetic concept of glaucomatous optic neuropathy?. Surv. Ophthalmol. 52 Suppl. 2 (2007) S162-S173
60. Frazer A., Maayani S., and Wolfe B.B. Subtypes of receptors for serotonin. Annu. Rev. Pharmacol. Toxicol. 30 (1990) 307-348
61. Garcia-Valenzuela E., Shareef S., Walsh J., and Sharma S.C. Programmed cell death of retinal ganglion cells during experimental glaucoma. Exp. Eye Res. 61 (1995) 33-44
62. Garthwaite G., Brown G., Batchelor A.M., Goodwin D.A., and Garthwaite J. Mechanisms of ischaemic damage to central white matter axons: a quantitative histological analysis using rat optic nerve. Neuroscience 94 (1999) 1219-1230
63. Gaspar A.Z., Flammer J., and Hendrickson P. Influence of nifedipine on the visual fields of patients with optic-nerve-head diseases. Eur. J. Ophthalmol. 4 (1994) 24-28
64. Gaspar A.Z., Gasser P., and Flammer J. The influence of magnesium on visual field and peripheral vasospasm in glaucoma. Ophthalmologica 209 (1995) 11-13
65. Gasser P., and Flammer J. Influence of vasospasm on visual function. Doc Ophthalmol. 66 (1987) 3-18
66. Gasser P., and Flammer J. Short- and long-term effect of nifedipine on the visual field in patients with presumed vasospasm. J. Int. Med. Res. 18 (1990) 334-339
67. Geyer O., Neudorfer M., Kessler A., Firsteter E., Lazar M., and Almog Y. Effect of oral nifedipine on ocular blood flow in patients with low tension glaucoma. Br. J. Ophthalmol. 80 (1996) 1060-1062
68. Greenfield D.S., Liebmann J.M., Ritch R., and Krupin T. Visual field and intraocular pressure asymmetry in the low-pressure glaucoma treatment study. Ophthalmology 114 (2007) 460-465
69. Grieshaber M.C., Terhorst T., and Flammer J. The pathogenesis of optic disc splinter haemorrhages: a new hypothesis. Acta Ophthalmol. Scand. 84 (2006) 62-68
70. Grieshaber M.C., Mozaffarieh M., and Flammer J. What is the link between vascular dysregulation and glaucoma?. Surv. Ophthalmol. 52 Suppl 2 (2007) S144-S154
71. Grieshaber M.C., and Flammer J. Blood flow in glaucoma. Curr. Opin. Ophthalmol. 16 (2005) 79-83
72. Grieshaber M.C., and Flammer J. Does the blood-brain barrier play a role in Glaucoma?. Surv. Ophthalmol. 52 Suppl. 2 (2007) S115-S121
73. Gupta A., Chen H.C., Rassam S.M., and Kohner E.M. Effect of betaxolol on the retinal circulation in eyes with ocular hypertension: a pilot study. Eye 8 Pt 6 (1994) 668-671
74. Haefliger I.O., Fleischhauer J., and Flammer J. Pharmacological mechanisms pf action of drugs commonly used to treat glaucoma patients. In: Orgul S., and Flammer J. (Eds). Pharmacotherapy in Glaucoma (2000), Hans Huber Verlag, Bern 17-23
75. Haefliger I.O., Lietz A., Griesser S.M., Ulrich A., Schotzau A., Hendrickson P., and Flammer J. Modulation of Heidelberg retinal flowmeter parameter flow at the papilla of healthy subjects: effect of carbogen, oxygen, high intraocular pressure, and beta-blockers. Surv. Ophthalmol. 43 Suppl. 1 (1999) S59-S65
76. Haefliger I.O., and Hitchings R.A. Relationship between asymmetry of visual field defects and intraocular pressure difference in an untreated normal (low) tension glaucoma population. Acta Ophthalmol. (Copenh) 68 (1990) 564-567
77. 2+ channel blocker as an anti-glaucoma drug: effects on ocular circulation and retinal neuronal damage. Cardiovasc. Drug Rev. 22 (2004) 199-214
78. Harris A., Spaeth G.L., Sergott R.C., Katz L.J., Cantor L.B., and Martin B.J. Retrobulbar arterial hemodynamic effects of betaxolol and timolol in normal-tension glaucoma. Am. J. Ophthalmol. 120 (1995) 168-175
79. Harris A., Evans D.W., Cantor L.B., and Martin B. Hemodynamic and visual function effects of oral nifedipine in patients with normal-tension glaucoma. Am. J. Ophthalmol. 124 (1997) 296-302
80. He S., Prasanna G., and Yorio T. Endothelin-1-mediated signaling in the expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in astrocytes. Invest. Ophthalmol. Vis. Sci. 48 (2007) 3737-3745
81. Heijl A., Leske M.C., Bengtsson B., Hyman L., and Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch. Ophthalmol. 120 (2002) 1268-1279
82. Hester R.K., Chen Z., Becker E.J., McLaughlin M., and DeSantis L. The direct vascular relaxing action of betaxolol, carteolol and timolol in porcine long posterior ciliary artery. Surv. Ophthalmol. 38 Suppl. (1994) S125-S134
83. Higginbotham E.J., Gordon M.O., Beiser J.A., Drake M.V., Bennett G.R., Wilson M.R., and Kass M.A. The ocular hypertension treatment study: topical medication delays or prevents primary open-angle glaucoma in African American individuals. Arch. Ophthalmol. 122 (2004) 813-820
84. Hollo G., Whitson J.T., Faulkner R., McCue B., Curtis M., Wieland H., Chastain J., Sanders M., DeSantis L., Przydryga J., and Dahlin D.C. Concentrations of betaxolol in ocular tissues of patients with glaucoma and normal monkeys after 1 month of topical ocular administration. Invest. Ophthalmol. Vis. Sci. 47 (2006) 235-240
85. Hoste A.M. In vitro studies of the effects of beta-adrenergic drugs on retinal and posterior ciliary microarteries. Surv. Ophthalmol. 43 Suppl. 1 (1999) S183-S190
86. Hoste A.M., and Sys S.U. The relaxant action of betaxolol on isolated bovine retinal microarteries. Curr. Eye Res. 13 (1994) 483-487
87. 2+ channel-blocking activity of propranolol and betaxolol in isolated bovine retinal microartery. J. Cardiovasc. Pharmacol. 32 (1998) 390-396
88. Inoue-Matsuhisa E., Moroi S.E., Takenaka H., Sogo S., and Mano T. 5- HT(2) receptor-mediated phosphoinositide hydrolysis in bovine ciliary epithelium. J. Ocul. Pharmacol. Ther. 19 (2003) 55-62
89. Ishida K., Yamamoto T., and Kitazawa Y. Clinical factors associated with progression of normal-tension glaucoma. J. Glaucoma 7 (1998) 372-377
90. Jampel H.D., Lynch M.G., Brown R.H., Kuhar M.J., and De Souza E.B. Beta-adrenergic receptors in human trabecular meshwork. Identification and autoradiographic localization. Invest. Ophthalmol. Vis. Sci. 28 (1987) 772-779
91. 2+ channel blockers on directional selectivity of rabbit retinal ganglion cells. J. Neurophysiol. 74 (1995) 12-23
92. Ju W.K., Kim K.Y., Park S.J., Park D.K., Park C.B., Oh S.J., Chung J.W., and Chun M.H. Nitric oxide is involved in sustained and delayed cell death of rat retina following transient ischemia. Brain Res. 881 (2000) 231-236
93. Ju W.K., Lindsey J.D., Angert M., Patel A., and Weinreb R.N. Glutamate receptor activation triggers OPA1 release and induces apoptotic cell death in ischemic rat retina. Mol. Vis. 14 (2008) 2629-2638
94. Kaiser H.J., Flammer J., Stumpfig D., and Hendrickson P. Longterm visual field follow-up of glaucoma patients treated with beta-blockers. Surv. Ophthalmol. 38 Suppl. (1994) S156-S159 discussion S160
95. Kass M.A., Heuer D.K., Higginbotham E.J., Johnson C.A., Keltner J.L., Miller J.P., Parrish II R.K., Wilson M.R., and Gordon M.O. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open- angle glaucoma. Arch. Ophthalmol. 120 (2002) 701-713 discussion 829-730
96. Kaufman P.L. Adenosine 3',5'-cyclic-monophosphate and outflow facility in monkey eyes with intact and retrodisplaced ciliary muscle. Exp. Eye Res. 44 (1987) 415-423
97. Kerrigan L.A., Zack D.J., Quigley H.A., Smith S.D., and Pease M.E. TUNEL-positive ganglion cells in human primary open-angle glaucoma. Arch. Ophthalmol. 115 (1997) 1031-1035
98. Kiel J.W., and Patel P. Effects of timolol and betaxolol on choroidal blood flow in the rabbit. Exp. Eye Res. 67 (1998) 501-507
99. Kim J.H., Kim D.M., and Park W.C. Effect of betaxolol on impaired choroidal blood flow after intravitreal injection of endothelin-1 in albino rabbits. J. Ocul. Pharmacol. Ther. 18 (2002) 203-209
100. 2(+)-antagonist on visual field in low-tension glaucoma. Graefes Arch. Clin. Exp. Ophthalmol. 227 (1989) 408-412
101. Kobayashi T., Oku H., Fukuhara M., Kojima S., Komori A., Ichikawa M., Katsumura K., Kobayashi M., Sugiyama T., and Ikeda T. Endothelin-1 enhances glutamate-induced retinal cell death, possibly through ETA receptors. Invest. Ophthalmol. Vis. Sci. 46 (2005) 4684-4690
102. Kobilka B.K., Frielle T., Collins S., Yang-Feng T., Kobilka T.S., Francke U., Lefkowitz R.J., and Caron M.G. An intron less gene encoding a potential member of the family of receptors coupled to guanine nucleotide regulatory proteins. Nature 329 (1987) 75-79
103. Koseki N., Araie M., Yamagami J., Shirato S., and Yamamoto S. Effects of oral brovincamine on visual field damage in patients with normal-tension glaucoma with low-normal intraocular pressure. J. Glaucoma 8 (1999) 117-123
104. Koseki N., Araie M., Tomidokoro A., Nagahara M., Hasegawa T., Tamaki Y., and Yamamoto S. A placebo-controlled 3-year study of a calcium blocker on visual field and ocular circulation in glaucoma with low-normal pressure. Ophthalmology 115 (2008) 2049-2057
105. Kristian T., and Siesjo B.K. Calcium in ischemic cell death. Stroke 29 (1998) 705-718
106. Lam T.T., Siew E., Chu R., and Tso M.O. Ameliorative effect of MK-801 on retinal ischemia. J. Ocul. Pharmacol. Ther. 13 (1997) 129-137
107. Langlois M., Bremont B., Rousselle D., and Gaudy F. Structural analysis by the comparative molecular field analysis method of the affinity of beta-adrenoreceptor blocking agents for 5-HT1A and 5-HT1B receptors. Eur. J. Pharmacol. 244 (1993) 77-87
108. Leske M.C., Heijl A., Hussein M., Bengtsson B., Hyman L., and Komaroff E. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch. Ophthalmol. 121 (2003) 48-56
109. Leske M.C., Heijl A., Hyman L., Bengtsson B., Dong L., and Yang Z. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology 114 (2007) 1965-1972
110. Li S., and Stys P.K. Mechanisms of ionotropic glutamate receptor-mediated excitotoxicity in isolated spinal cord white matter. J. Neurosci. 20 (2000) 1190-1198
111. Lichter P.R., Musch D.C., Gillespie B.W., Guire K.E., Janz N.K., Wren P.A., and Mills R.P. Interim clinical outcomes in the collaborative initial glaucoma treatment study comparing initial treatment randomized to medications or surgery. Ophthalmology 108 (2001) 1943-1953
112. Liu H.K., and Chiou C.Y. Continuous, simultaneous, and instant display of aqueous humor dynamics with a micro-spectrophotometer and a sensitive drop counter. Exp. Eye Res. 32 (1981) 583-592
113. Liu S., Araujo S.V., Spaeth G.L., Katz L.J., and Smith M. Lack of effect of calcium channel blockers on open-angle glaucoma. J. Glaucoma 5 (1996) 187-190
114. Lograno M.D., and Reibaldi A. Receptor-responses in fresh human ciliary muscle. Br. J. Pharmacol. 87 (1986) 379-385
115. Louzada-Junior P., Dias J.J., Santos W.F., Lachat J.J., Bradford H.F., and Coutinho-Netto J. Glutamate release in experimental ischaemia of the retina: an approach using microdialysis. J. Neurochem. 59 (1992) 358-363
116. Luksch A., Rainer G., Koyuncu D., Ehrlich P., Maca T., Gschwandtner M.E., Vass C., and Schmetterer L. Effect of nimodipine on ocular blood flow and colour contrast sensitivity in patients with normal tension glaucoma. Br. J. Ophthalmol. 89 (2005) 21-25
117. Martin X.D., Brennan M.C., and Lichter P.R. Serotonin in human aqueous humor. Ophthalmology 95 (1988) 1221-1226
118. Martin X.D., and Rabineau P.A. Vasoconstrictive effect of topical timolol on human retinal arteries. Graefes Arch. Clin. Exp. Ophthalmol. 227 (1989) 526-530
119. Mastropasqua L., Costagliola C., Ciancaglini M., Carpineto P., and Gallenga P.E. Ocular hypotensive effect of ketanserin in patients with primary open angle glaucoma. Acta Ophthalmol. Scand. Suppl. (1997) 24-25
120. 2+ channels. Eur. J. Pharmacol. 378 (1999) 317-322
121. Melena J., Stanton D., and Osborne N.N. Comparative effects of antiglaucoma drugs on voltage-dependent calcium channels. Graefes Arch. Clin. Exp. Ophthalmol. 239 (2001) 522-530
122. Messmer C., Flammer J., and Stumpfig D. Influence of betaxolol and timolol on the visual fields of patients with glaucoma. Am. J. Ophthalmol 112 (1991) 678-681
123. Miki H., and Miki K. The effects on the intraocular pressure and visual field resulting from a switch in the treatment from timolol to betaxolol. J. Ocul. Pharmacol. Ther. 20 (2004) 509-517
124. Muskens R.P., de Voogd S., Wolfs R.C., Witteman J.C., Hofman A., de Jong P.T., Stricker B.H., and Jansonius N.M. Systemic antihypertensive medication and incident open-angle glaucoma. Ophthalmology 114 (2007) 2221-2226
125. Narushima I., Kita T., Kubo K., Yonetani Y., Momochi C., Yoshikawa I., Shimada K., and Nakashima T. Contribution of endothelin-1 to disruption ofblood-brain barrier permeability in dogs. Naunyn Schmiedebergs Arch. Pharmacol. 360 (1999) 639-645
126. Narushima I., Kita T., Kubo K., Yonetani Y., Momochi C., Yoshikawa I., Ohno N., and Nakashima T. Highly enhanced permeability of blood-brain barrier induced by repeated administration of endothelin-1 in dogs and rats. Pharmacol. Toxicol. 92 (2003) 21-26
127. Nathanson J.A. Human ciliary process adrenergic receptor: pharmacological characterization. Invest. Ophthalmol. Vis. Sci. 21 (1981) 798-804
128. Nathanson J.A. Stereospecificity of beta adrenergic antagonists: R-enantiomers show increased selectivity for beta-2 receptors in ciliary process. J. Pharmacol. Exp. Ther. 245 (1988) 94-101
129. Netland P.A., Chaturvedi N., and Dreyer E.B. Calcium channel blockers in the management of low-tension and open-angle glaucoma. Am. J. Ophthalmol. 115 (1993) 608-613
130. Nickells R.W., and Zack D.J. Apoptosis in ocular disease: a molecular overview. Ophthalmic Genet. 17 (1996) 145-165
131. Nicolela M.T., Buckley A.R., Walman B.E., and Drance S.M. A comparative study of the effects of timolol and latanoprost on blood flow velocity of the retrobulbar vessels. Am. J. Ophthalmol. 122 (1996) 784-789
132. Nielsen P.J., and Nyborg N.C. Adrenergic responses in isolated bovine retinal resistance arteries. Int. Ophthalmol. 13 (1989) 103-107
133. Niwa Y., Yamamoto T., Harris A., Kagemann L., Kawakami H., and Kitazawa Y. Relationship between the effect of carbon dioxide inhalation or nilvadipine on orbital blood flow in normal-tension glaucoma. J. Glaucoma 9 (2000) 262-267
134. Nyborg N.C., and Nielsen P.J. Beta-adrenergic receptors regulating vascular smooth muscle tone are only localized to the intraocular segment of the long posterior ciliary artery in bovine eye. Surv. Ophthalmol. 39 Suppl. 1 (1995) S66-S75
135. Ohtake Y., Tanino T., Kimura I., Mashima Y., and Oguchi Y. Long-term efficacy and safety of combined topical antiglaucoma therapy-timolol & unoprostone vs. betaxolol & unoprostone. Nippon Ganka Gakkai Zasshi 108 (2004) 23-28
136. Okisaka S., Murakami A., Mizukawa A., and Ito J. Apoptosis in retinal ganglion cell decrease in human glaucomatous eyes. Jpn. J. Ophthalmol. 41 (1997) 84-88
137. Orgul S., Mansberger S., Bacon D.R., Van Buskirk E.M., and Cioffi G.A. Optic nerve vasomotor effects of topical beta-adrenergic antagonists in rabbits. Am. J. Ophthalmol. 120 (1995) 441-447
138. Orgul S., and Flammer J. Interocular visual-field and intraocular-pressure asymmetries in normal-tension-glaucoma. Eur. J. Ophthalmol. 4 (1994) 199-201
139. Orrenius S., Ankarcrona M., and Nicotera P. Mechanisms of calcium-related cell death. Adv. Neurol. 71 (1996) 137-149 discussion 149-151
140. Osborne N.N. Memantine reduces alterations to the mammalian retina, in situ, induced by ischemia. Vis. Neurosci. 16 (1999) 45-52
141. Osborne N.N., and Chidlow G. Do beta-adrenoceptors and serotonin 5-HT1A receptors have similar functions in the control of intraocular pressure in the rabbit?. Ophthalmologica 210 (1996) 308-314
142. Osborne N.N., Cazevieille C., Carvalho A.L., Larsen A.K., and DeSantis L. In vivo and in vitro experiments show that betaxolol is a retinal neuroprotective agent. Brain Res. 751 (1997) 113-123
143. Osborne N.N., DeSantis L., Bae J.H., Ugarte M., Wood J.P., Nash M.S., and Chidlow G. Topically applied betaxolol attenuates NMDA-induced toxicity to ganglion cells and the effects of ischaemia to the retina. Exp. Eye Res. 69 (1999) 331-342
144. Osborne N.N., Ugarte M., Chao M., Chidlow G., Bae J.H., Wood J.P., and Nash M.S. Neuroprotection in relation to retinal ischemia and relevance to glaucoma. Surv. Ophthalmol. 43 Suppl. 1 (1999) S102-S128
145. Osborne N.N., Chidlow G., Melena J., Nash M.S., and Wood J.P. Protection from ganglion cell death by substance that act on calcium channels. In: Orgul S., and Flammer J. (Eds). Pharmacotherapy in glaucoma (2000), Hans Huber Verlag, Bern 251-275
146. Osborne N.N., Wood J.P., Cupido A., Melena J., and Chidlow G. Topical flunarizine reduces IOP and protects the retina against ischemia-excitotoxicity. Invest. Ophthalmol. Vis. Sci. 43 (2002) 1456-1464
147. Osborne N.N., Wood J.P., Chidlow G., Casson R., DeSantis L., and Schmidt K.G. Effectiveness of levobetaxolol and timolol at blunting retinal ischaemia is related to their calcium and sodium blocking activities: relevance to glaucoma. Brain Res. Bull. 62 (2004) 525-528
148. Osborne N.N., Wood J.P., and Chidlow G. Invited review: neuroprotective properties of certain beta-adrenoceptor antagonists used for the treatment of glaucoma. J. Ocul. Pharmacol. Ther. 21 (2005) 175-181
149. Pache M., and Flammer J. A sick eye in a sick body? Systemic findings in patients with primary open-angle glaucoma. Surv. Ophthalmol. 51 (2006) 179-212
150. Peroutka S.J. 5-Hydroxytryptamine receptor subtypes. Pharmacol. Toxicol. 67 (1990) 373-383
151. Pillunat L.E., Lang G.K., and Harris A. The visual response to increased ocular blood flow in normal pressure glaucoma. Surv. Ophthalmol. 38 Suppl (1994) S139-S147 discussion S147-138
152. Piltz J.R., Bose S., and Lanchoney D. The effect of nimodipine, a centrally active calcium antagonist, on visual function and mascular blood flow in patients with normal-tension glaucoma and control subjects. J. Glaucoma 7 (1998) 336-342
153. Polansky J., Friedman Z., Fauss D., Kurtz R., and Alvarado J. Effects of betaxolol/timolol on epinephrine stimulated cyclic-AMP levels in human trabecular meshwork cells. Int. Ophthalmol. 13 (1989) 95-97
154. Prasanna G., Krishnamoorthy R., Clark A.F., Wordinger R.J., and Yorio T. Human optic nerve head astrocytes as a target for endothelin-1. Invest. Ophthalmol. Vis. Sci. 43 (2002) 2704-2713
155. Rahn K.H., Hawlina A., Kersting F., and Planz G. Studies on the antihypertensive action of the optical isomers of propranolol in man. Naunyn Schmiedebergs Arch. Pharmacol. 286 (1974) 319-323
156. Rainer G., Dorner G.T., Garhofer G., Vass C., Pfleger T., and Schmetterer L. Changing antiglaucoma therapy from timolol to betaxolol: effect on ocular blood flow. Ophthalmologica 217 (2003) 288-293
157. Rowland J.M., and Potter D.E. Steric structure activity relationships of various adrenergic agonists: ocular and systemic effects. Curr. Eye Res. 1 (1981) 25-35
158. Salminen L., and Urtti A. Disposition of ophthalmic timolol in treated and untreated rabbit eyes. A multiple and single dose study. Exp. Eye Res. 38 (1984) 203-206
159. (2+) concentration induced by hypoxia in retinal ganglion cells. Jpn. J. Ophthalmol. 51 (2007) 175-180
160. Sato T., Muto T., Ishibashi Y., and Roy S. Short-term effect of beta-adrenoreceptor blocking agents on ocular blood flow. Curr. Eye Res. 23 (2001) 298-306
161. Sawada A., Kitazawa Y., Yamamoto T., Okabe I., and Ichien K. Prevention of visual field defect progression with brovincamine in eyes with normal-tension glaucoma. Ophthalmology 103 (1996) 283-288
162. Schmetterer L., Strenn K., Findl O., Breiteneder H., Graselli U., Agneter E., Eichler H.G., and Wolzt M. Effects of antiglaucoma drugs on ocular hemodynamics in healthy volunteers. Clin. Pharmacol. Ther. 61 (1997) 583-595
163. Schmidt K.G., Mittag T.W., Pavlovic S., and Hessemer V. Influence of physical exercise and nifedipine on ocular pulse amplitude. Graefes Arch. Clin. Exp. Ophthalmol. 234 (1996) 527-532
164. Schmitt C.J., Lotti V.J., and LeDouarec J.C. Penetration of timolol into the rabbit eye. Measurements after ocular instillation and intravenous injection. Arch. Ophthalmol. 98 (1980) 547-551
165. Sears M.L. Regulation of aqueous flow by the adenylate cyclase receptor complex in the ciliary epithelium. Am. J. Ophthalmol. 100 (1985) 194-198
166. Share N.N., Lotti V.J., Gautheron P., Schmitt C., Gross D.M., Hall R.A., and Stone C.A. R-enantiomer of timolol: a potential selective ocular antihypertensive agent. Graefes Arch. Clin. Exp. Ophthalmol. 221 (1984) 234-238
167. Shigeeda T., Tomidokoro A., Araie M., Koseki N., and Yamamoto S. Long- term follow-up of visual field progression after trabeculectomy in progressive normal-tension glaucoma. Ophthalmology 109 (2002) 766-770
168. (2+) exchanger in cultured rat astrocytes. Brain Res. 887 (2000) 98-109
169. Sonntag J.R., Brindley G.O., and Shields M.B. Effect of timolol therapy on outflow facility. Invest. Ophthalmol. Vis. Sci. 17 (1978) 293-296
170. Sponsel W.E. Sustained perimacular vascular and visual response to topical beta blockers in normal human eyes. Brain Res. Bull. 62 (2004) 529-535
171. Sponsel W.E., Kaufman P.L., and Blum Jr. F.G. Association of retinal capillary perfusion with visual status during chronic glaucoma therapy. Ophthalmology 104 (1997) 1026-1032
172. Stewart R.H., Kimbrough R.L., and Ward R.L. Betaxolol vs timolol. A six- month double-blind comparison. Arch. Ophthalmol. 104 (1986) 46-48
173. Stokely M.E., Yorio T., and King M.A. Endothelin-1 modulates anterograde fast axonal transport in the central nervous system. J. Neurosci. Res. 79 (2005) 598-607
174. Stys P.K. Protective effects of antiarrhythmic agents against anoxic injury in CNS white matter. J. Cereb. Blood Flow Metab. 15 (1995) 425-432
175. Stys P.K. White matter injury mechanisms. Curr. Mol. Med. 4 (2004) 113-130
176. 2+ exchanger. J. Neurosci. 12 (1992) 430-439
177. Stys P.K., Hubatsch D.A., and Leppanen L.L. Effects of K+ channel blockers on the anoxic response of CNS myelinated axons. Neuroreport 9 (1998) 447-453
178. Stys P.K., and Lopachin R.M. Mechanisms of calcium and sodium fluxes in anoxic myelinated central nervous system axons. Neuroscience 82 (1998) 21-32
179. Takahashi K., Lam T.T., Edward D.P., Buchi E.R., and Tso M.O. Protective effects of flunarizine on ischemic injury in the rat retina. Arch. Ophthalmol. 110 (1992) 862-870
180. Tamaki Y., Araie M., Tomita K., and Nagahara M. Effect of topical betaxolol on tissue circulation in the human optic nerve head. J. Ocul. Pharmacol. Ther. 15 (1999) 313-321
181. Tan A.Y., LeVatte T.L., Archibald M.L., Tremblay F., Kelly M.E., and Chauhan B.C. Timolol concentrations in rat ocular tissues and plasma after topical and intraperitoneal dosing. J. Glaucoma 11 (2002) 134-142
182. Taniguchi T., Shimazawa M., Sasaoka M., Shimazaki A., and Hara H. Endothelin-1 impairs retrograde axonal transport and leads to axonal injury in rat optic nerve. Curr. Neurovasc. Res. 3 (2006) 81-88
183. Tasindi E., and Talu H. Differential effect of betaxolol and timolol on the progression of glaucomatous visual field loss. In: Drance S.M. (Ed). Vascular Risk Factors and Neuroprotection in Glaucoma - Update 1996 (1997), Kugler, Amsterdam/New York 227-234
184. Tekat D., Guler C., Arici M., Topalkara A., and Erdogan H. Effect of ketanserin administration on intraocular pressure. Ophthalmologica 215 (2001) 419-423
185. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am. J. Ophthalmol. 130 (2000) 429-440
186. Tobin A.B., Unger W., and Osborne N.N. Evidence for the presence of serotonergic nerves and receptors in the iris-ciliary body complex of the rabbit. J. Neurosci. 8 (1988) 3713-3721
187. Tocco D.J., Hooke K.F., Deluna F.A., and Duncan A.E. Stereospecific binding of timolol, a beta-adrenergic blocking agent. Drug Metab. Dispos 4 (1976) 323-329
188. Tomita G., Niwa Y., Shinohara H., Hayashi N., Yamamoto T., and Kitazawa Y. Changes in optic nerve head blood flow and retrobular hemodynamics following calcium-channel blocker treatment of normal-tension glaucoma. Int. Ophthalmol. 23 (1999) 3-10
189. 2+ channel blocker, reduces glutamate- induced neurotoxicity and ischemia/reperfusion damage in rat retina. Exp. Eye Res. 70 (2000) 475-484
190. Turacli M.E., Ozden R.G., and Gurses M.A. The effect of betaxolol on ocular blood flow and visual fields in patients with normotension glaucoma. Eur. J. Ophthalmol. 8 (1998) 62-66
191. Uji Y., Kuze M., Matubara H., Doi M., and Sasoh M. Effects of the beta1-selective adrenergic antagonist betaxolol on electroretinography in the perfused cat eye. Doc. Ophthalmol. 106 (2003) 37-41
192. Vainio-Jylha E., and Vuori M.L. The favorable effect of topical betaxolol and timolol on glaucomatous visual fields: a 2-year follow-up study. Graefes Arch. Clin. Exp. Ophthalmol 237 2 (1999) 100-104
193. Vainio-Jylha E., Vuori M.L., and Nummelin K. Progression of retinal nerve fibre layer damage in betaxolol- and timolol-treated glaucoma patients. Acta Ophthalmol. Scand. 80 (2002) 495-500
194. Vogel R., Tipping R., Kulaga S.F., and Clineschmidt C.M. Changing therapy from timolol to betaxolol. Effect on intraocular pressure in selected patients with glaucoma. Arch. Ophthalmol. 107 (1989) 1303-1307 Timolol-Betaxolol Study Group
195. Wang Y., Ju W., Liu L., Fam S., D'Souza S., Taghibiglou C., Salter M., and Wang Y.T. Alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid subtype glutamate receptor (AMPAR) endocytosis is essential for N-methyl-d-aspartate-induced neuronal apoptosis. J. Biol. Chem. 279 (2004) 41267-41270
196. Watson P.G., Barnett M.F., Parker V., and Haybittle J. A 7 year prospective comparative study of three topical beta blockers in the management of primary open angle glaucoma. Br. J. Ophthalmol. 85 (2001) 962-968
197. Wax M.B., Molinoff P.B., Alvarado J., and Polansky J. Characterization of beta-adrenergic receptors in cultured human trabecular cells and in human trabecular meshwork. Invest. Ophthalmol. Vis. Sci. 30 (1989) 51-57
198. Wax M.B., and Molinoff P.B. Distribution and properties of beta-adrenergic receptors in human iris-ciliary body. Invest. Ophthalmol. Vis. Sci. 28 (1987) 420-430
199. Weber J., Koll W., and Krieglstein G.K. Intraocular pressure and visual field decay in chronic glaucoma. Ger. J. Ophthalmol. 2 (1993) 165-169
200. Wilson R.P., Chang W.J., Sergott R.C., Moster M.R., Schmidt C.M., Bond J.B., and Harris A. A color Doppler analysis of nifedipine-induced posterior ocular blood flow changes in open-angle glaucoma. J. Glaucoma 6 (1997) 231-236
201. Wood J.P., DeSantis L., Chao H.M., and Osborne N.N. Topically applied betaxolol attenuates ischaemia-induced effects to the rat retina and stimulates BDNF mRNA. Exp. Eye Res. 72 (2001) 79-86
202. Wood J.P., Schmidt K.G., Melena J., Chidlow G., Allmeier H., and Osborne N.N. The beta-adrenoceptor antagonists metipranolol and timolol are retinal neuroprotectants: comparison with betaxolol. Exp. Eye Res. 76 (2003) 505-516
203. Yamamoto T., Niwa Y., Kawakami H., and Kitazawa Y. The effect of nilvadipine, a calcium-channel blocker, on the hemodynamics of retrobulbar vessels in normal-tension glaucoma. J. Glaucoma 7 (1998) 301-305
204. Yu D.Y., Su E.N., Alder V.A., Cringle S.J., and Mele E.M. Pharmacological and mechanical heterogeneity of cat isolated opthalmociliary artery. Exp. Eye Res. 54 (1992) 347-359
205. Yu D.Y., Su E.N., Cringle S.J., Alder V.A., Yu P.K., and Desantis L. Effect of betaxolol, timolol and nimodipine on human and pig retinal arterioles. Exp. Eye Res. 67 (1998) 73-81
206. Yu M., Gopalakrishnan V., and McNeill J.R. Hemodynamic effects of a selective endothelin - a receptor antagonist in deoxycorticosterone acetate-salt hypertensive rats. J. Cardiovasc. Pharmacol. 31 Suppl. 1 (1998) S262-S264
207. Yucel Y.H., Gupta N., Zhang Q., Mizisin A.P., Kalichman M.W., and Weinreb R.N. Memantine protects neurons from shrinkage in the lateral geniculate nucleus in experimental glaucoma. Arch. Ophthalmol. 124 (2006) 217-225
208. Zetterstrom C., and Hahnenberger R. Pharmacological characterization of human ciliary muscle adrenoceptors in vitro. Exp. Eye Res. 46 (1988) 421-430